Newer Parameters of the Octreotide Test in Patients with Acromegaly

Overview

Journal Pituitary

Specialty Endocrinology

Date 2023 Nov 24

PMID 37999819

Authors

Shin Urai

Masaaki Yamamoto

Naoki Yamamoto

Masaki Suzuki

Hiroki Shichi

Keitaro Kanie

Yasunori Fujita

Hironori Bando

Hidenori Fukuoka

Michiko Takahashi

Genzo Iguchi

Yutaka Takahashi

Wataru Ogawa

Affiliations

Soon will be listed here.

Abstract

Purpose: Predicting the therapeutic effects of first-generation somatostatin receptor ligands (fg-SRLs) is important when assessing or planning effective treatment strategies in patients with acromegaly. The oft-used maximum growth hormone (GH) suppression rate parameter of the octreotide test has a suboptimal predictive value. Therefore, this study explored newer parameters of the octreotide test for predicting the therapeutic effect of long-acting fg-SRLs.

Methods: In this single-center retrospective study, the octreotide test parameters and the therapeutic effects of fg-SRL at 3 months were investigated in 45 consecutive treatment-naïve patients with acromegaly between April 2008 and March 2023. Additionally, the relationship between the octreotide test parameters and the therapeutic effects of fg-SRLs was investigated. Tumor shrinkage was evaluated based on changes in the longitudinal diameter of the macroadenomas. The area GH suppression rate-time under the curve (AUC) and the time to nadir GH level were calculated and compared with the maximum GH suppression rate.

Results: The AUC estimated reductions in serum insulin-like growth factor I, and tumor shrinkage. The time to nadir GH level predicted tumor shrinkage more robustly than the maximum GH suppression rate in patients with macroadenoma.

Conclusion: The AUC and time to nadir GH level may potentially be newer parameters of the octreotide test for estimating the therapeutic effect of fg-SRLs.

Citing Articles

Metyrapone single administration, as a possible predictive tool of its dosage and timing in Cushing's syndrome.

Tsujimoto Y, Yamamoto N, Bando H, Yamamoto M, Ohmachi Y, Motomura Y Front Endocrinol (Lausanne). 2025; 15():1511155.

PMID: 39764253 PMC: 11700816. DOI: 10.3389/fendo.2024.1511155.

References

Fleseriu M, Langlois F, Lim D, Varlamov E, Melmed S . Acromegaly: pathogenesis, diagnosis, and management. Lancet Diabetes Endocrinol. 2022; 10(11):804-826. DOI: 10.1016/S2213-8587(22)00244-3. View

Melmed S, Bronstein M, Chanson P, Klibanski A, Casanueva F, Wass J . A Consensus Statement on acromegaly therapeutic outcomes. Nat Rev Endocrinol. 2018; 14(9):552-561. PMC: 7136157. DOI: 10.1038/s41574-018-0058-5. View

Cuevas-Ramos D, Carmichael J, Cooper O, Bonert V, Gertych A, Mamelak A . A structural and functional acromegaly classification. J Clin Endocrinol Metab. 2014; 100(1):122-31. PMC: 4283008. DOI: 10.1210/jc.2014-2468. View

Carmichael J, Bonert V, Nuno M, Ly D, Melmed S . Acromegaly clinical trial methodology impact on reported biochemical efficacy rates of somatostatin receptor ligand treatments: a meta-analysis. J Clin Endocrinol Metab. 2014; 99(5):1825-33. PMC: 4010703. DOI: 10.1210/jc.2013-3757. View

Gadelha M, Kasuki L, Korbonits M . Novel pathway for somatostatin analogs in patients with acromegaly. Trends Endocrinol Metab. 2012; 24(5):238-46. DOI: 10.1016/j.tem.2012.11.007. View

Fleseriu M, Biller B, Freda P, Gadelha M, Giustina A, Katznelson L . A Pituitary Society update to acromegaly management guidelines. Pituitary. 2020; 24(1):1-13. PMC: 7864830. DOI: 10.1007/s11102-020-01091-7. View

Ilie M, Tabarin A, Vasiljevic A, Bonneville J, Moreau-Grange L, Schillo F . Predictive Factors of Somatostatin Receptor Ligand Response in Acromegaly-A Prospective Study. J Clin Endocrinol Metab. 2022; 107(11):2982-2991. DOI: 10.1210/clinem/dgac512. View

Gadelha M, Wildemberg L, Kasuki L . The Future of Somatostatin Receptor Ligands in Acromegaly. J Clin Endocrinol Metab. 2021; 107(2):297-308. PMC: 8764337. DOI: 10.1210/clinem/dgab726. View

Halperin I, Nicolau J, Casamitjana R, Sesmilo G, Serra-Prat M, Palomera E . A short acute octreotide test for response prediction of long-term treatment with somatostatin analogues in acromegalic patients. Horm Metab Res. 2008; 40(6):422-6. DOI: 10.1055/s-2008-1065339. View

10.

Taboada G, Donangelo I, Guimaraes R, Silva M, Fontes R, Gadelha M . [Acute test with subcutaneous octreotide as a predictor of the response to treatment with octreotide LAR]. Arq Bras Endocrinol Metabol. 2006; 49(3):390-5. DOI: 10.1590/s0004-27302005000300010. View

11.

de Herder W, Taal H, Uitterlinden P, Feelders R, Janssen J, van der Lely A . Limited predictive value of an acute test with subcutaneous octreotide for long-term IGF-I normalization with Sandostatin LAR in acromegaly. Eur J Endocrinol. 2005; 153(1):67-71. DOI: 10.1530/eje.1.01935. View

12.

Colao A, Pivonello R, Auriemma R, Galdiero M, Savastano S, Grasso L . Growth hormone-secreting tumor shrinkage after 3 months of octreotide-long-acting release therapy predicts the response at 12 months. J Clin Endocrinol Metab. 2008; 93(9):3436-42. DOI: 10.1210/jc.2008-0424. View

13.

Colao A, Auriemma R, Lombardi G, Pivonello R . Resistance to somatostatin analogs in acromegaly. Endocr Rev. 2010; 32(2):247-71. DOI: 10.1210/er.2010-0002. View

14.

Petersenn S, Houchard A, Sert C, Caron P . Predictive factors for responses to primary medical treatment with lanreotide autogel 120 mg in acromegaly: post hoc analyses from the PRIMARYS study. Pituitary. 2019; 23(2):171-181. PMC: 7066297. DOI: 10.1007/s11102-019-01020-3. View

15.

Giustina A, Di Filippo L, Uygur M, Frara S . Modern approach to resistant acromegaly. Endocrine. 2023; 80(2):303-307. DOI: 10.1007/s12020-023-03317-7. View

16.

Katznelson L, Laws Jr E, Melmed S, Molitch M, Murad M, Utz A . Acromegaly: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2014; 99(11):3933-51. DOI: 10.1210/jc.2014-2700. View

17.

Hagiwara A, Inoue Y, Wakasa K, Haba T, Tashiro T, Miyamoto T . Comparison of growth hormone-producing and non-growth hormone-producing pituitary adenomas: imaging characteristics and pathologic correlation. Radiology. 2003; 228(2):533-8. DOI: 10.1148/radiol.2282020695. View

18.

Isojima T, Shimatsu A, Yokoya S, Chihara K, Tanaka T, Hizuka N . Standardized centile curves and reference intervals of serum insulin-like growth factor-I (IGF-I) levels in a normal Japanese population using the LMS method. Endocr J. 2012; 59(9):771-80. DOI: 10.1507/endocrj.ej12-0110. View

19.

Colao A, Ferone D, Lastoria S, Marzullo P, Cerbone G, Di Sarno A . Prediction of efficacy of octreotide therapy in patients with acromegaly. J Clin Endocrinol Metab. 1996; 81(6):2356-62. DOI: 10.1210/jcem.81.6.8964877. View

20.

Yamamoto M, Fukuoka H, Iguchi G, Matsumoto R, Takahashi M, Nishizawa H . The prevalence and associated factors of colorectal neoplasms in acromegaly: a single center based study. Pituitary. 2014; 18(3):343-51. DOI: 10.1007/s11102-014-0580-y. View